The tool, the Cryosection Histopathology Assessment and Review Machine, or CHARM, is a machine-learning algorithm that was trained by researchers showing it sample photos collected during brain surgeries and comparing its work with each respective diagnosis, according to a July 7 report from Bloomberg.
Knowing the genetic profile of a tumor is necessary for surgeons to know how much brain tissue to remove during surgery and whether to implant drug-coated wafers to start fighting the cancer. The speed at which the tool can provide this information allows clinicians to make immediate decisions, eliminating time-consuming testing and helping patients avoid multiple surgeries, according to Kun-Hsing Yu, MD, PhD, assistant professor of biomedical informatics at Boston-based Harvard Medical School and author of the study.
CHARM was also able to distinguish malignant from benign tumors and grade a tumor’s severity, the report said.
While the study revealed the tool is more effective than any other AI system, it is still not as accurate as current genetic tests. Researchers said it still needs to be tested in real-world settings before it can officially help physicians make treatment decisions, according to Bloomberg.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
